PH12021550037A1 - Pharmaceutical composition in the form of a chewable tablet of diosmin or of a flavonoid moiety - Google Patents
Pharmaceutical composition in the form of a chewable tablet of diosmin or of a flavonoid moietyInfo
- Publication number
- PH12021550037A1 PH12021550037A1 PH12021550037A PH12021550037A PH12021550037A1 PH 12021550037 A1 PH12021550037 A1 PH 12021550037A1 PH 12021550037 A PH12021550037 A PH 12021550037A PH 12021550037 A PH12021550037 A PH 12021550037A PH 12021550037 A1 PH12021550037 A1 PH 12021550037A1
- Authority
- PH
- Philippines
- Prior art keywords
- pharmaceutical composition
- diosmin
- chewable tablet
- flavonoid moiety
- pcnt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Disclosed is a pharmaceutical composition in the form of a chewable tablet containing a high dose of micronized diosmin. Said pharmaceutical composition comprises micronized diosmin amounting to 20 pcnt to 80 pcnt of the total weight of the pharmaceutical composition. The disclosed pharmaceutical composition is used in the treatment of venous insufficiency and hemorrhoidal crises.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1856769A FR3083980B1 (en) | 2018-07-20 | 2018-07-20 | PHARMACEUTICAL COMPOSITION IN THE FORM OF A CHEWABLE TABLET OF DIOSMINE OR A FLAVONOIC FRACTION |
| PCT/EP2019/069498 WO2020016408A1 (en) | 2018-07-20 | 2019-07-19 | Pharmaceutical composition in the form of a chewable tablet of diosmin or of a flavonoid moiety |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12021550037A1 true PH12021550037A1 (en) | 2021-09-27 |
Family
ID=65243687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12021550037A PH12021550037A1 (en) | 2018-07-20 | 2021-01-07 | Pharmaceutical composition in the form of a chewable tablet of diosmin or of a flavonoid moiety |
Country Status (36)
| Country | Link |
|---|---|
| EP (2) | EP3823588B1 (en) |
| KR (1) | KR20210034036A (en) |
| CN (2) | CN119345141A (en) |
| AR (1) | AR117612A1 (en) |
| AU (1) | AU2019306315B2 (en) |
| BR (1) | BR112021000440A2 (en) |
| CA (1) | CA3106495C (en) |
| CL (1) | CL2021000083A1 (en) |
| CO (1) | CO2021000115A2 (en) |
| CR (1) | CR20210023A (en) |
| DK (1) | DK3823588T3 (en) |
| EA (1) | EA202190269A1 (en) |
| EC (1) | ECSP21001232A (en) |
| ES (1) | ES2991941T3 (en) |
| FI (1) | FI3823588T3 (en) |
| FR (1) | FR3083980B1 (en) |
| GE (1) | GEP20237532B (en) |
| HR (1) | HRP20250037T1 (en) |
| HU (1) | HUE069700T2 (en) |
| JO (1) | JOP20210003A1 (en) |
| LT (1) | LT3823588T (en) |
| MA (1) | MA53159B1 (en) |
| MD (1) | MD3823588T2 (en) |
| MX (1) | MX2021000763A (en) |
| MY (1) | MY200586A (en) |
| NI (1) | NI202100002A (en) |
| PE (1) | PE20210929A1 (en) |
| PH (1) | PH12021550037A1 (en) |
| PL (1) | PL3823588T3 (en) |
| PT (1) | PT3823588T (en) |
| RS (1) | RS66288B1 (en) |
| SG (1) | SG11202100181YA (en) |
| SI (1) | SI3823588T1 (en) |
| TW (1) | TWI831808B (en) |
| UA (1) | UA128677C2 (en) |
| WO (1) | WO2020016408A1 (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2661610B1 (en) * | 1990-05-02 | 1994-09-30 | Rhone Poulenc Sante | NOVEL LYOPHILIZED FORM OF DIOSMINE AND ITS PREPARATION. |
| FR2661830B1 (en) * | 1990-05-11 | 1992-09-04 | Corbiere Jerome | NOVEL PHARMACEUTICAL COMPOSITIONS BASED ON FLAVONOSIDE. |
| FR2726469B1 (en) | 1994-11-08 | 1996-12-13 | Adir | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF FLAVONOIDS |
| FR2845597B1 (en) * | 2002-10-11 | 2005-03-11 | Innothera Lab Sa | DRY ORAL FORMULATION CONTAINING DIOSMINE AS A PHARMACEUTICAL FORM OF A TABLET TO BE CROQUERED |
| ITMI20050517A1 (en) | 2005-03-30 | 2006-09-30 | Therapicon Srl | PHARMACEUTICAL COMPOSITION OF A TYPICAL MICROCRYSTALLINE FRACTION OF FLAVONOIDS |
| FR2999934B1 (en) * | 2012-12-21 | 2015-02-20 | Servier Lab | PHARMACEUTICAL COMPOSITION IN THE FORM OF AN ORAL SUSPENSION COMPRISING A FLAVONOIC FRACTION AND XANTHAN GUM |
-
2018
- 2018-07-20 FR FR1856769A patent/FR3083980B1/en active Active
-
2019
- 2019-07-19 GE GEAP202315564A patent/GEP20237532B/en unknown
- 2019-07-19 MY MYPI2021000084A patent/MY200586A/en unknown
- 2019-07-19 DK DK19742363.5T patent/DK3823588T3/en active
- 2019-07-19 HU HUE19742363A patent/HUE069700T2/en unknown
- 2019-07-19 UA UAA202100556A patent/UA128677C2/en unknown
- 2019-07-19 BR BR112021000440-8A patent/BR112021000440A2/en unknown
- 2019-07-19 PE PE2021000077A patent/PE20210929A1/en unknown
- 2019-07-19 RS RS20241369A patent/RS66288B1/en unknown
- 2019-07-19 KR KR1020217004706A patent/KR20210034036A/en not_active Ceased
- 2019-07-19 PT PT197423635T patent/PT3823588T/en unknown
- 2019-07-19 MX MX2021000763A patent/MX2021000763A/en unknown
- 2019-07-19 CA CA3106495A patent/CA3106495C/en active Active
- 2019-07-19 WO PCT/EP2019/069498 patent/WO2020016408A1/en not_active Ceased
- 2019-07-19 AR ARP190102031A patent/AR117612A1/en unknown
- 2019-07-19 LT LTEPPCT/EP2019/069498T patent/LT3823588T/en unknown
- 2019-07-19 TW TW108125532A patent/TWI831808B/en active
- 2019-07-19 FI FIEP19742363.5T patent/FI3823588T3/en active
- 2019-07-19 HR HRP20250037TT patent/HRP20250037T1/en unknown
- 2019-07-19 CR CR20210023A patent/CR20210023A/en unknown
- 2019-07-19 CN CN202411465581.6A patent/CN119345141A/en active Pending
- 2019-07-19 PL PL19742363.5T patent/PL3823588T3/en unknown
- 2019-07-19 EA EA202190269A patent/EA202190269A1/en unknown
- 2019-07-19 SI SI201930858T patent/SI3823588T1/en unknown
- 2019-07-19 CN CN201980047436.7A patent/CN112423735A/en active Pending
- 2019-07-19 SG SG11202100181YA patent/SG11202100181YA/en unknown
- 2019-07-19 ES ES19742363T patent/ES2991941T3/en active Active
- 2019-07-19 AU AU2019306315A patent/AU2019306315B2/en active Active
- 2019-07-19 MA MA53159A patent/MA53159B1/en unknown
- 2019-07-19 EP EP19742363.5A patent/EP3823588B1/en active Active
- 2019-07-19 JO JOP/2021/0003A patent/JOP20210003A1/en unknown
- 2019-07-19 EP EP24208148.7A patent/EP4473977A3/en active Pending
- 2019-07-19 MD MDE20210479T patent/MD3823588T2/en unknown
-
2021
- 2021-01-07 PH PH12021550037A patent/PH12021550037A1/en unknown
- 2021-01-08 NI NI202100002A patent/NI202100002A/en unknown
- 2021-01-08 EC ECSENADI20211232A patent/ECSP21001232A/en unknown
- 2021-01-08 CO CONC2021/0000115A patent/CO2021000115A2/en unknown
- 2021-01-12 CL CL2021000083A patent/CL2021000083A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550328A1 (en) | Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject | |
| ZA202110659B (en) | Methods of reducing the risk of cardiovascular events in a subject | |
| EP4223316A3 (en) | Improved antibody-oligonucleotide conjugate | |
| ES2176190T3 (en) | INHIBITORS OF THE ACTIVITY OF SEX STEROIDS. | |
| BR0109672A (en) | Use of zd6126 or a pharmaceutically acceptable salt thereof and one of: a plantin antitumor agent and a taxane, pharmaceutical composition, combination product, kit, and method for producing a vascularly damaging effect on a warm-blooded animal | |
| ES2062100T3 (en) | USE OF ACETYL L-CARNITINE IN THE THERAPEUTIC TREATMENT OF CATARACTS AND PHARMACEUTICAL COMPOSITIONS USEFUL IN THIS TREATMENT. | |
| BR112021017957A2 (en) | Thienoeterocyclic derivative, method of preparation thereof and medical use thereof | |
| ZA201905212B (en) | Rescue treatment of post operative nausea and vomiting | |
| BR112015028302A2 (en) | nicotine tablet formulation | |
| DOP2021000069A (en) | DERIVATIVES OF 4 PIRAZIN-2-ILMETIL-MORFOLINA AND THEIR USE AS A MEDICINAL PRODUCT | |
| BR7102525D0 (en) | PROCESS FOR THE PREPARATION OF A PHYTO FOOD COMPOSITION ADMINISTERED BY THE LEAVES AND TO PROVIDE ONE OR MORE PHYTONUTRITIVE ELEMENTS AND OR MINERAL SUPPLEMENTS TO PLANTS | |
| EA202190269A1 (en) | PHARMACEUTICAL COMPOSITION IN THE FORM OF A CHEWING TABLET OF DIOSMINE OR FLAVONOID FRACTION | |
| MX2024001832A (en) | Oral composition comprising a mdm2-antagonist for cancer therapy. | |
| ECSP22092205A (en) | LEVILIMAB AQUEOUS PHARMACEUTICAL COMPOSITION AND ITS USE | |
| BR112021026471A2 (en) | Solid dose formulations for needle-free delivery | |
| GB976096A (en) | Pharmaceutical compositions | |
| GB1292496A (en) | Dosage units of contraceptive preparations for human use | |
| AR063712A1 (en) | TREATMENT OF PAIN USING SATRAPLATINO | |
| IL36127A0 (en) | Novel esters of the pregnane series,their preparation and pharmaceutical compositions containing them | |
| GB1300486A (en) | Compositions for the treatment of respiratory ailments in man | |
| ZA202310640B (en) | Methods of reducing the risk of heart failure | |
| PH12021500016A1 (en) | Methods of reducing the risk of cardiovascular events in a subject | |
| NL154217B (en) | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS IN WHICH ONE PUTS 11-ALKOXY-3-KETOSTEROIDS WITH AN OXYGEN FUNCTION IN THE 17-PLACE IN MEDICAL USE FORM OF ADMINISTRATION, THE PREPARED MEDICINAL PRODUCTS, AS PREPARED MEDICINAL PRODUCTS, AS PREPARED PREPARATIONS. | |
| GB1191180A (en) | Therapeutic Composition | |
| ES336131A1 (en) | Nicotinic Acid Esters having Pharmacological Properties and the preparation thereof |